Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71205-258

7 FDA label images from Proficient Rx Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 71205-258). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph depicting the percentage of subjects with systolic blood pressure (SBP) below 140 mmHg varying with baseline SBP (140 to 180 mmHg). Four treatments are compared: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The graph shows a decreasing trend in percentage below 140 mmHg as baseline SBP increases for all groups.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph comparing the percentage of DBP (diastolic blood pressure) below 90 mmHg versus baseline DBP in mmHg, for four groups: Valsartan HCT 320/25 mg (filled circles), Valsartan 320 mg (open triangles), Hydrochlorothiazide 25 mg (open squares), and Placebo (crosses). The graph shows decreasing % DBP<90 as baseline DBP increases from 90 to 110 mmHg.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line graph showing the percentage of patients with systolic blood pressure (SBP) below 130 mmHg plotted against baseline SBP (140 to 180 mmHg). The chart compares four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, illustrating their respective effects on SBP reduction.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A graph showing the percentage of patients achieving diastolic blood pressure (DBP) under 80 mmHg plotted against baseline DBP (mmHg). The graph compares treatment effects of Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, with symbols differentiating each treatment group.*
FDA Label Image

Hydrochlorothiazide (Hydrochlorothiazide)

Hydrochlorothiazide (Hydrochlorothiazide)
Chemical structure of the active ingredient depicted in the image, showing the molecular arrangement including rings, sulfonamide, and chloro substituents, likely corresponding to one of the components in Valsartan and Hydrochlorothiazide tablets.*
FDA Label Image

71205-258-30 (Image 01)

71205-258-30 (Image 01)
Label for Valsartan and Hydrochlorothiazide 160 mg / 12.5 mg film-coated tablets by Proficient Rx LP. The label states a quantity of 30 tablets, with identification of the active ingredients and strengths. Tablets are described as dark red, oval, biconvex film-coated, debossed with "L17" on one side. Manufactured by Macleods Pharmaceuticals Ltd in India. Includes NDC 71205-258-30 and storage instructions.*
FDA Label Image

Valsartan (Valsartan)

Valsartan (Valsartan)
Chemical structure diagram of Valsartan, one of the active ingredients in Valsartan and Hydrochlorothiazide tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.